Fisher et al. reported that there were trends towards higher C-reactive protein (CRP), DAS28 (CRP) and also greater use of methotrexate in the anti-citrullinated α-enolase peptide 1 (CEP-1)+/CCP2+ subset than in the anti-CEP-1-/CCP2+ subset in one cohort (Norfolk Arthritis Register cohort, p = 0.08) [47]. This evidence concerns the gene CRP and arthritic joint disease.